Skip to content

BeiGene, Ltd. Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 5, 2026 results vs estimates

BeiGene, Ltd. · E.ONC.NASDAQ · United States
Use symbol E.ONC.NASDAQ in our API & Excel add-in to retrieve this data ↓
371.56
(0.00%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 34.31%

BeiGene, Ltd. Forecast

BeiGene, Ltd. short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 34.3% a year, a typical one-standard-deviation range is 353.60–389.52 over a week, 334.76–408.36 over a month and 244.09–499.03 over a year. (Signals as of 1 Nov 2026.)

BeiGene, Ltd. Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
BeiGene, Ltd.
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
BeiGene, Ltd.
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
BeiGene, Ltd.
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
BeiGene, Ltd.
P/E
47.60x
Cheap vs own history
QoQ −28.0%
YoY −91.8%
now 47.604747.6 low604.99 high
ⓘP/E As of 22 Nov 2026.See BeiGene, Ltd. returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
BeiGene, Ltd.
P/S
6.60x
Mid-range vs own history
QoQ −6.8%
YoY −17.6%
now 6.59745.34 low8.34 high
ⓘP/S As of 22 Nov 2026.See BeiGene, Ltd. returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
BeiGene, Ltd.
P/B
7.49x
Mid-range vs own history
QoQ −10.6%
YoY −22.3%
now 7.48846.43 low10.04 high
ⓘP/B As of 22 Nov 2026.See BeiGene, Ltd. returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
BeiGene, Ltd.
EV/EBITDA
27.28x
Cheap vs own history
QoQ −19.7%
YoY −74.4%
now 27.283927.28 low111.4 high
ⓘEV/EBITDA As of 22 Nov 2026.See BeiGene, Ltd. returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
BeiGene, Ltd.
EV/Sales
5.90x
Mid-range vs own history
QoQ −8.3%
YoY −20.3%
now 5.89624.7 low7.73 high
ⓘEV/Sales As of 22 Nov 2026.See BeiGene, Ltd. returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
BeiGene, Ltd.
FCF Yield
2.8%
Strong vs own history
QoQ +10.4%
YoY +136.1%
now 2.75481.12 low2.76 high
ⓘFCF Yield As of 22 Nov 2026.See BeiGene, Ltd. returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
BeiGene, Ltd.
Earnings Yield
2.1%
Strong vs own history
QoQ +38.9%
YoY +1,120.2%
now 2.10060.17 low2.1 high
ⓘEarnings Yield As of 22 Nov 2026.See BeiGene, Ltd. returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
BeiGene, Ltd.
Market Cap
$43.6B
Highest in 5 years
QoQ +0.5%
YoY +9.5%
now 43585.548630,619 low48,862 high
ⓘMarket Cap As of 22 Nov 2026.See BeiGene, Ltd. returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
BeiGene, Ltd.
Net Debt
-$4.6B
Mid-range vs own history
QoQ +17.1%
YoY +53.5%
now -4632.362-4,632 low-2,548 high
ⓘNet Debt As of 22 Nov 2026.See BeiGene, Ltd. returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
BeiGene, Ltd.
Net Debt / EBITDA
-3.24x
High vs own history
QoQ −4.9%
YoY −62.9%
now -3.2446-8.74 low-3.24 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See BeiGene, Ltd. returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
BeiGene, Ltd.
Current Ratio
3.55x
Mid-range vs own history
QoQ +4.3%
YoY +48.4%
now 3.55042.39 low3.64 high
ⓘCurrent Ratio As of 22 Nov 2026.See BeiGene, Ltd. returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
BeiGene, Ltd.
Quick Ratio
3.19x
Mid-range vs own history
QoQ +4.2%
YoY +47.1%
now 3.18872.17 low3.27 high
ⓘQuick Ratio As of 22 Nov 2026.See BeiGene, Ltd. returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
BeiGene, Ltd.
Interest Coverage
7.56x
Strong vs own history
QoQ +10.8%
YoY —
now 7.56095.44 low7.56 high
ⓘInterest Coverage As of 22 Nov 2026.See BeiGene, Ltd. returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
BeiGene, Ltd.
Debt / Equity
0.20x
Mid-range vs own history
QoQ −10.7%
YoY −20.1%
now 0.19740.2 low0.46 high
ⓘDebt / Equity As of 22 Nov 2026.See BeiGene, Ltd. returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
BeiGene, Ltd.
Piotroski F-Score
8
Strong vs own history
QoQ 0.0%
YoY 0.0%
now 87 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See BeiGene, Ltd. returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
BeiGene, Ltd.
Altman Z-Score
7.19
Strong vs own history
QoQ +2.7%
YoY +10.0%
now 7.18824.97 low7.97 high
ⓘAltman Z-Score As of 22 Nov 2026.See BeiGene, Ltd. returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  20 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for BeiGene, Ltd., red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

BeiGene, Ltd. fundamentals: income statement, balance sheet & cash flow

BeiGene, Ltd. reported revenue of $5.34bn and net income of $286.9m in FY2025, the year ended 31 December 2025 — revenue up 40.2% and net income up 144.5% on the prior year. Free cash flow was $941.7m. These figures are as reported in the filings, not restated: 13 fiscal years and 51 quarters of history, back to December 2013. 44 FINRA short-interest settlements are published alongside them, back to January 2025.

Revenue (FY2025)
$5.34bn
+40.2%
Net income
$286.9m
+144.5%
Gross margin
87.49%
Free cash flow
$941.7m
+240.6%
Net debt
-$2.55bn
Shares short (30 Oct 2026)
1.60m
4.37 days to cover
BeiGene, Ltd. income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue5,343.03,810.22,458.81,415.91,176.3
Cost of revenue668.5594.1379.9286.5164.9
Gross profit4,674.53,216.22,078.91,129.41,011.4
Research & development2,145.91,953.31,778.61,640.51,459.2
Selling, general & admin.2,081.51,831.11,508.01,278.6990.1
Operating income447.1-568.2-1,207.7-1,789.7-1,438.7
EBITDA616.8-361.2-738.2-1,894.8-1,392.1
Interest expense58.221.84.452.5—
Pre-tax income416.9-533.0-825.8-1,961.0-1,438.6
Income tax129.9111.855.942.819.2
Net income286.9-644.8-881.7-2,003.8-1,457.8

Download BeiGene, Ltd. fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ONC.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 13 fiscal years and 51 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on BeiGene, Ltd.

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

BeiGene, Ltd. Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to BeiGene, Ltd.; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How BeiGene, Ltd.’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how BeiGene, Ltd. behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About BeiGene, Ltd. (United States)

BeiGene, Ltd. is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on BeiGene, Ltd.

Frequently asked questions

What is BeiGene, Ltd.?
BeiGene, Ltd. is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest BeiGene, Ltd. price?
The latest close is 371.56 (1 Nov 2026), -0.00% on the day. The price at the top of the page refreshes during the trading day.
Is BeiGene, Ltd. in an uptrend?
As of 1 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is BeiGene, Ltd.?
20-day realised volatility is 34.3% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 9.9% over a month and 4.8% over a week.
What factors affect BeiGene, Ltd.?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to BeiGene, Ltd., grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade BeiGene, Ltd.?
58 backtested tactical asset allocation strategies trade BeiGene, Ltd. through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are BeiGene, Ltd. returns analysed?
The Statistical Distribution of Returns section shows the distribution of BeiGene, Ltd. daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free BeiGene, Ltd. historical data?
In the Free historical data section of this page: the last 10 years of BeiGene, Ltd. daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free BeiGene, Ltd. historical data (last 10 years)

Browse or instantly download the last 10 years of BeiGene, Ltd. daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ONC.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20390.94
2026-11-19399.7
2026-11-18403.6
2026-11-17413.26
2026-11-16411.29
2026-11-13416.54
2026-11-12415.96
2026-11-11419.98
2026-11-10424
2026-11-09417.33
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.